THE Therapeutic Goods Administration (TGA) has confirmed a review of all COVID-19-specific laboratory antigen tests and rapid antigen tests (RATs), including point-of-care and self-tests, which are included in the Australian Register of Therapeutic Goods.
The review aims to determine if the tests have been impacted by the current known variants of SARS-CoV-2, with ongoing activity to assess their ability to detect emerging variants of COVID-19.
The TGA noted that as each Variant of Concern (VoC) emerges, manufacturers are expected to undertake analysis to ensure their tests continue to perform as intended.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jun 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jun 22
